Titan Pharmaceuticals

$3.25
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.06 (-1.85%) Today

+$0.06 (+1.88%) As of 10:10 AM UTC after-hours

Why Robinhood?

You can buy or sell TTNP and other stocks, options, and ETFs commission-free!

About TTNP

Titan Pharmaceuticals, Inc. engages in development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, ProNeura. Its lead product is Probuphine, a buprenorphine implant for the maintenance treatment of opioid addiction. The company was founded by Louis R. Bucalo in February 7, 1992 and is headquartered in South San Francisco, CA. The listed name for TTNP is Titan Pharmaceuticals, Inc. Common Stock.

CEO

Sunil Bhonsle, MBA

Employees

Headquarters

South San Francisco, California

Founded

1992

Market Cap

21.40M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

1.58M

High Today

$3.27

Low Today

$3.16

Open Price

$3.22

Volume

922.42K

52 Week High

$16.35

52 Week Low

$2.82

Collections

TTNP Earnings

-$0.38

-$0.25

-$0.13

$0.00

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Mar 30, Pre-Market